MA H4489

Health Policy Commission gains authority to require drug manufacturers to disclose pricing information, including 5-year wholesale acquisition cost history, R&D expenditures, and justifications for price changes

Drugs referred for commission review include those costing over $50,000 annually per patient, biosimilars not priced at least 15% below reference biologics, and the top 25 drugs with greatest impact on health care spending

Commission must issue determination within 60 days on whether drug pricing is unreasonable or excessive, then recommend cost-reduction measures such as bulk purchasing, value-based payment, or changes to cost-sharing requirements

Manufacturers face civil penalties up to $500,000 for failing to comply with information requests or providing false/misleading information

Insurance carriers must conduct annual audits of pharmacy benefit managers and require PBMs to obtain state licensure as a condition of contracting